Business Wire

HYTERA

Share
Hytera, an Entrusted Partner Elevating Global Critical Communication Networks

Technology underpins the successful running of all kinds of mega events. Audiences these days are constantly amazed by the top-notch technologies adopted by the Beijing 2022 Winter Olympics and Paralympic Winter Games. Among them, the professional mobile radios (PMR), which support critical communications of the world-class event, have earned wide attention from the public.

As one of the key communication solution suppliers of Beijing 2022 Winter Olympic and Paralympic Winter Games, Hytera provided a certain amount of TETRA devices, PMR-LTE convergent solutions and command & control systems to the security officers and rescue teams during the races. Hytera’s communication technologies also played a major role in the execution of COVID-19 prevention in the Olympic Village.

In fact, besides the global mega sport events, Hytera’s products and solutions are also chosen by industry clients across public safety, transportation, manufacturing, oil and gas as well as the retail and hospitality industries.

Innovation Is in Hytera’s DNA

With continuous investment in technology innovation, Hytera is committed to promoting open communication standards from narrowband to broadband, including TETRA, DMR, PDT and LTE with independent intellectual property rights, which makes it a leading provider of professional communication solutions.

Hytera recently added the H Series to its DMR product portfolios. The new series is built from the ground up on an entirely new technology platform. It is the first of its kind in the industry when it comes to functionality, user experience, and ruggedness, providing efficient and reliable communications to users in security, education industry and customer service roles as well as those working in severe working conditions.

Global Recognition and Partnership Achieved by Hytera

To meet the growing needs of business and critical communication users, Hytera innovatively developed a variety of products and technology solutions. Among them, there are DMR terminals, TETRA terminals, PoC Radios, multimode advanced radios, body worn cameras, command & dispatch and emergency response software that have contributed to the success of users working in the vertical industries, such as public safety, energy, transportation, utility, commercial and operator markets. With audio, visual and data capabilities, Hytera has provided faster, safer, and more versatile connectivity options.

Hytera has showcased its technological strength and achieved global recognition and partnerships. The International Critical Communications Awards (ICAA) awarded Hytera the “Best New LTE or Hybrid Device” for its LTE & TETRA convergent device PTC760, as well as the “Best Use of Critical Communications in Utilities” in recognition of its Hytalk PoC solution for Turkey Electricity Company.

Global partnerships have also validated Hytera’s competence. Hytera played a role in the 2021 FIFA Arab Cup and the 2018 FIFA World Cup with its local partners. Hytera also worked with the security department in Tajikistan during the SCO Summit 2021.

Supporting Communities under Global Challenges

While succeeding in landing international business partnerships, Hytera has also contributed its capacities to tackle global challenges.

To deal with the outbreak of the COVID-19 pandemic, Hytera has actively contributed its capabilities to improve disease prevention. Hytera’s two way radios and pandemic prevention solutions provided fast and reliable non-contact communication to the workers from hospitals, enterprises and security departments around the world to fight against the virus.

As a key player in the critical communications industry, Hytera, empowered by top-performing technologies, will continue to support industrial users, and ensure safer and stronger communication networks worldwide.

Link:

ClickThru

Social Media:

https://www.facebook.com/Hytera.Global

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye